Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.770
-0.330-3.63%
Volume:150.35M
Turnover:1.32B
Market Cap:101.05B
PE:22.09
High:9.090
Open:8.900
Low:8.705
Close:9.100
52wk High:10.943
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.39
T/O Rate:1.30%
Dividend:0.34
Dividend Rate:3.84%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.30
PE(LYR):22.09
PS:2.76

Loading ...

Southbound Capital Daily: Net Selloff Hits HK$10.41B, Alibaba Draws Mainland Buying Pre-Earnings, Healthcare Stocks Split

Stock News
·
Aug 20

Hong Kong Stocks Rise on Thursday on Easing Bond Concerns, Tech Gains; CSPC Pharma Jumps 9%

MT Newswires Live
·
Aug 20

CSPC Pharma Surges 15% as Moderna's mRNA Cancer Vaccine Hits Key Milestone

Stock News
·
Aug 20

Norway's Vistin Pharma Q2 Revenue Falls on Currency Impact

Reuters
·
Aug 20

CSPC Pharma (01093) Surges Over 12% After Interim Profit Jumps Nearly 1.4-Fold

Stock News
·
Aug 20

CSPC Pharmaceutical Hits 6-Month High on Profit, Dividend Surge

Reuters
·
Aug 20

CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%

MT Newswires Live
·
Aug 20

CSPC Pharma FY26 H1 Profit Attributable to Shareholders More than Doubled to RMB 6.09 Billion; Revenue Rises 40.1% to RMB 18.59 Billion

Reuters
·
Aug 20

CSPC Pharmaceutical Group H1 Net Income Attributable RMB 6,094.2 Million

THOMSON REUTERS
·
Aug 20

CSPC Pharmaceutical Group - Interim Dividend of HK18 Cents Per Share for 2026

THOMSON REUTERS
·
Aug 20

Movement Alert|CSPC PHARMA Rises 12.49% in Regular Trading, Interim Results Day Coupled with Multiple Positive Catalysts

Market Focus
·
Aug 20

CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China

Bulletin Express
·
Aug 19

CSPC Pharmaceutical Group Stock Sheds 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 19

Does FDA-Backed Mpox mRNA Trial and AstraZeneca Tie-Up Recast the Bull Case For CSPC (SEHK:1093)?

Simply Wall St.
·
Aug 19

CSPC Pharma Says NMPA Accepts NDA for KN026 and Hb1801 for Advanced Breast Cancer

Reuters
·
Aug 18

CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live
·
Aug 18

Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer

Reuters
·
Aug 18

CSPC Pharmaceutical - Kn026 and Hb1801 Combination Previously Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS
·
Aug 18

CSPC Pharmaceutical - Nda Indication: First-Line Treatment of Unresectable or Metastatic Her2-Positive Breast Cancer

THOMSON REUTERS
·
Aug 18

CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue

Reuters
·
Aug 17